New Mexico Administrative Code › Title 16 - OCCUPATIONAL AND PROFESSIONAL LICENSING › Chapter 19 - PHARMACISTS › Part 4 - PHARMACIST › Section 16.19.4.7 - DEFINITIONS

Current through Register Vol. 35, No. 13, July 16, 2024
A.
"A year"
begins with the pharmacist's birth month and ends the last day of the pharmacist's birth month the following year.
B.
"Accredited Provider"
An institution, organization or agency that has been recognized by the Accreditation Council for Pharmacy Education, in accord with its policy and procedures, as having demonstrated compliance with the standards which are indicative of the Provider's capability to develop and deliver quality continuing pharmacy education.
C.
"Activity"
as used in the ACPE criteria for quality and these regulations, the term refers to an individual educational experience or program such as a lecture, home study course, workshop, seminar, symposium, etc.
D.
"Alternate supervising physician"
means a physician who holds a current unrestricted license, is a cosignatory on the notification of supervision, agrees to act as the supervising physician in the supervising physician's absence, or expand the "scope of practice or sites of practice" of the pharmacist clinician and is approved by the board.
E.
"Board"
means the New Mexico board of pharmacy.
F.
"Consultation"
means communication in person, telephonically, by two-way radio, by e-mail or by other electronic means.
G.
"Contact hour"
means a unit of measure equivalent to 60 minutes of participation in an approved organized learning experience or activity.
H.
"Continuing education unit (CEU)"
means ten contact hours of participation or it ' s equivalent in an organized continuing education activity sponsored by an accredited provider.
I.
"Continuing pharmacy education (CPE)"
means a structured education activity offered by an accredited provider, designed or intended to support the continuing development of pharmacies or pharmacy technicians to maintain and enhance their competence. Continuing pharmacy education should promote problem-solving and critical thinking and be applicable to the practice of pharmacy.
J.
"Continuing professional development (CPD)"
means the responsibility of individual pharmacists for systematic maintenance, development and broadening of knowledge, skills and attitudes, to ensure continuing competence as a professional, throughout their careers.
K.
"Criteria for quality"
means continuing education provider shall show evidence of adherence to the criteria adopted by the American council on pharmaceutical education as indicative of the ability to provide continuing pharmaceutical education activities; areas include: administrative and organization; budget and resources; teaching staff; educational content management of activity; method of delivery; facilities; evaluation mechanism.
L.
"Dangerous drug"
means a drug that, because of any potentiality for harmful effect or the methods of its use or the collateral measures necessary to its use, is not safe except under the supervision of a provider licensed by law to direct the use of such drug and the drug prior to dispensing is required by federal law and state law to bear the manufacturer's legend "Caution: Federal law prohibits dispensing without a prescription;" or "Caution: federal law restricts this drug to use by or on the order of a licensed veterinarian."; or "Rx only."
M.
"Guidelines or protocol"
means a written agreement between a pharmacist clinician or group of pharmacist clinicians and a physician or group of physicians that delegates prescriptive authority.
N.
"Initial pharmacist licensure"
means the license issued shall be valid for no less than 24 months. The license will expire the last date of his/her birth month that immediately follows the minimum 24 month time period.
O.
"Live programs"
means CPE activities that provide for direct interaction between faculty and participants and may include lectures, symposia, live teleconferences, workshops, etc.
P.
"Monitor dangerous drug therapy"
means to review the dangerous drug therapy regimen of patients by a pharmacist clinician for the purpose of evaluating and rendering advice regarding adjustment of the regimen. "Monitor dangerous drug therapy" includes:
(1) collecting and reviewing patient dangerous drug histories;
(2) measuring and reviewing routine patient vital signs including pulse, temperature, blood pressure and respiration;
(3) ordering and evaluating the results of laboratory tests relating to dangerous drug therapy, including blood chemistries and cell counts, controlled substance therapy levels, blood, urine, tissue or other body fluids, culture and sensitivity tests when performed in accordance with guidelines or protocols applicable to the practice setting and;
(4) evaluating situations that require the immediate attention of the physician and instituting or modifying treatment procedures when necessary.